Imperial College London
Portrait Picture

Professor Hashim Ahmed

Faculty of Medicine, Department of Surgery & Cancer

Chair in Urology (Clinical)
 
 
 
//

Contact

 

hashim.ahmed

 
 
//

Location

 

5L28Lab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{van:2019:10.1007/s00345-019-02636-7,
author = {van, Luijtelaar A and Greenwood, BM and Ahmed, HU and Barqawi, AB and Barret, E and Bomers, JGR and Brausi, MA and Choyke, PL and Cooperberg, MR and Eggener, S and Feller, JF and Frauscher, F and George, AK and Hindley, RG and Jenniskens, SFM and Klotz, L and Kovacs, G and Lindner, U and Loeb, S and Margolis, DJ and Marks, LS and May, S and Mcclure, TD and Montironi, R and Nour, SG and Oto, A and Polascik, TJ and Rastinehad, AR and De, Reyke TM and Reijnen, JS and de, la Rosette JJMCH and Sedelaar, JPM and Sperling, DS and Walser, EM and Ward, JF and Villers, A and Ghai, S and Fütterer, JJ},
doi = {10.1007/s00345-019-02636-7},
journal = {World Journal of Urology},
pages = {2147--2153},
title = {Focal laser ablation as clinical treatment of prostate cancer: Report from a Delphi consensus project},
url = {http://dx.doi.org/10.1007/s00345-019-02636-7},
volume = {37},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PURPOSE: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method. METHODS: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings. RESULTS: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation. CONCLUSION: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.
AU  - van,Luijtelaar A
AU  - Greenwood,BM
AU  - Ahmed,HU
AU  - Barqawi,AB
AU  - Barret,E
AU  - Bomers,JGR
AU  - Brausi,MA
AU  - Choyke,PL
AU  - Cooperberg,MR
AU  - Eggener,S
AU  - Feller,JF
AU  - Frauscher,F
AU  - George,AK
AU  - Hindley,RG
AU  - Jenniskens,SFM
AU  - Klotz,L
AU  - Kovacs,G
AU  - Lindner,U
AU  - Loeb,S
AU  - Margolis,DJ
AU  - Marks,LS
AU  - May,S
AU  - Mcclure,TD
AU  - Montironi,R
AU  - Nour,SG
AU  - Oto,A
AU  - Polascik,TJ
AU  - Rastinehad,AR
AU  - De,Reyke TM
AU  - Reijnen,JS
AU  - de,la Rosette JJMCH
AU  - Sedelaar,JPM
AU  - Sperling,DS
AU  - Walser,EM
AU  - Ward,JF
AU  - Villers,A
AU  - Ghai,S
AU  - Fütterer,JJ
DO  - 10.1007/s00345-019-02636-7
EP  - 2153
PY  - 2019///
SN  - 0724-4983
SP  - 2147
TI  - Focal laser ablation as clinical treatment of prostate cancer: Report from a Delphi consensus project
T2  - World Journal of Urology
UR  - http://dx.doi.org/10.1007/s00345-019-02636-7
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30671638
UR  - http://hdl.handle.net/10044/1/67097
VL  - 37
ER  -
Download